Study of HSK31679 in Subjects With Hypercholesterolemia With Nonalcoholic Fatty Liver Disease(NAFLD)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 210 participants.
Also called NCT05795517
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 210 participants
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Registry
-
NCT05795517
-
- Other papers using this trial's data
- Efficacy and Safety of HSK31679 in Asian Patients With MASLD: A Randomized Controlled Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT05795517. Randomized; double masking; primary purpose treatment. Start 2023-04-26 (actual); primary completion 2024-02-20 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of HSK31679 in Subjects With Hypercholesterolemia With Nonalcoholic Fatty Liver Disease(NAFLD)
- Condition
- Hypercholesterolemia
- Intervention (Drug)
- HSK31679 low dose
- Intervention (Drug)
- HSK31679 medium dose
- Intervention (Drug)
- HSK31679 high dose
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Ezetimibe 10mg
- Lead sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Record details
- Record id
cardio:ct-nct05795517- Content hash
f029eaa7771753d66cc6a9728f18a7e18743d8502e9fd0fb23baefd35d5f44b5